Type 2 diabetes trials in Argentina

In Argentina 21 Also abroad 1200

21 trials · From ClinicalTrials.gov, checked 11 November 2026. Ask the study team whether a trial fits you.

Phase 3Taking people
A Clinical Study to Evaluate the Effects of Enicepatide (RO7795068) in Participants With Obesity or Overweight Without Type 2 Diabetes
Where
Buenos Aires, Ciudad Autonoma Buenos Aires, Mar del Plata
Age
18 years and over
People
2,000 worldwide
Run by
Hoffmann-La Roche
See details and how to joinNCT07351045 · EU 2025-523104-71-00
Phase 3Taking people
A Clinical Study to Evaluate the Effects of Enicepatide (RO7795068) in Participants With Obesity or Overweight and Type 2 Diabetes
Where
Buenos Aires, Ciudad Autonoma Buenos Aires, Mar del Plata
Age
18 years and over
People
1,600 worldwide
Run by
Hoffmann-La Roche
See details and how to joinNCT07351058 · EU 2025-523106-32-00
Phase 3Taking people
A Study to Evaluate Effect of AZD6234 as an Adjunct to Incretin-based Therapies in Adult Participants With Obesity or Overweight With Weight-related Comorbidity With or Without Type 2 Diabetes Mellitus
Where
Buenos Aires, CABA, Ciudad de Buenos Aires, Ramos Mejía, Rosario, San Nicolás
Age
18 years and over
People
500 worldwide
Run by
AstraZeneca
See details and how to joinNCT07776509 · EU 2025-523295-23-00
Phase 2Taking people
A Study of Clazakizumab (LY5724886) in Adults With Elevated hsCRP and at Increased Risk for Cardiovascular Event
Where
Buenos Aires, Rosario, Santa Fe, Santa Rosa
Age
18 years and over
People
120 worldwide
Run by
Eli Lilly and Company
See details and how to joinNCT07783802
Phase 3Not yet taking people in Argentina
A Study of EloraTZP in Adult Participants With Obesity Without Type 2 Diabetes
Where
Bahía Blanca, Buenos Aires, Ciudad de Buenos Aires, Córdoba, Del Viso, Godoy Cruz, Granadero Baigorria, Junín, Mar del Plata, Mendoza, Rosario, SAN M. de Tucuman, Santiago del Estero
Age
18 years and over
People
2,115 worldwide
Run by
Eli Lilly and Company
See details and how to joinNCT07881432 · EU 2026-526047-34-00
Phase 2Not yet taking people in Argentina
A Study to Investigate the Effect of LY4086940 Versus Placebo in Participants With Obesity or Overweight and Without Type 2 Diabetes
Where
Buenos Aires, Rosario
Age
18 years to 75 years
People
460 worldwide
Run by
Eli Lilly and Company
See details and how to joinNCT07890376
Phase 3Not yet taking people in Argentina
A Study of Eloralintide (LY3841136) in Participants With Obesity or Overweight, Type 2 Diabetes, and Increased Cardiovascular Risk
Where
Buenos Aires, CABA, Córdoba, Granadero Baigorria, Lanus, Mar del Plata, Ramos Mejía, Rosario, San Fernando, San Nicolás, Santa Fe
Age
45 years to 64 years
People
3,000 worldwide
Run by
Eli Lilly and Company
See details and how to joinNCT07900633 · EU 2026-525919-14-00
Phase 3Taking people
A Phase III Study to Investigate the Efficacy and Safety of the Combination of Elecoglipron and Dapagliflozin in Adults With Type 2 Diabetes Mellitus
Where
Buenos Aires, CABA, Ciudad de Buenos Aires, Mar del Plata, Rosario, San Nicolás, San Vicente
Age
18 years and over
People
2,000 worldwide
Run by
AstraZeneca
See details and how to joinNCT07662109 · EU 2025-523941-81-00
Phase 3Taking people
A Study to Evaluate Effect of AZD6234 in Adult Participants With Obesity or Overweight With Weight-related Comorbidity Without Type 2 Diabetes Mellitus
Where
Buenos Aires, Ciudad de Buenos Aires, Mendoza, Ramos Mejía, Rosario, San Nicolás
Age
18 years and over
People
2,500 worldwide
Run by
AstraZeneca
See details and how to joinNCT07784725 · EU 2025-523379-41-00
Phase 3Taking people
EASi-PROTKT™ - A Study to Test Vicadrostat (BI 690517) Taken Together With Empagliflozin in People With Type 2 Diabetes, High Blood Pressure, and Cardiovascular Disease
Where
Bahía Blanca, Buenos Aires, CABA, Ciudad Autonoma Buenos Aires, Ciudad Autonoma de Bs As, Córdoba, Godoy Cruz, Granadero Baigorria, Mar del Plata, Parque Velez Sarsfield, Río Cuarto, Rosario, Santa Fe, Villa Luro
Age
18 years and over
People
11,800 worldwide
Run by
Boehringer Ingelheim
See details and how to joinNCT07064473 · EU 2025-521188-11-00
Phase 3Taking people
A Study to Evaluate Effect of AZD6234 in Adult Participants With Type 2 Diabetes Mellitus and Obesity or Overweight
Where
Buenos Aires, CABA, Ciudad de Buenos Aires, Mendoza, Ramos Mejía, Rosario, San Nicolás
Age
18 years and over
People
1,500 worldwide
Run by
AstraZeneca
See details and how to joinNCT07784270
Phase 3Taking people
A Study to Find Out if the Study Drug Elecoglipron Helps Adults With Type 2 Diabetes Mellitus by Comparing it With Semaglutide, a Medicine Already Used to Treat Type 2 Diabetes Mellitus
Where
Buenos Aires, CABA, Ciudad de Buenos Aires, Rosario, San Nicolás, San Vicente
Age
18 years and over
People
1,200 worldwide
Run by
AstraZeneca
See details and how to joinNCT07662213 · EU 2025-523933-24-00
Phase 3Taking people
A Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Placebo in Children and Adolescents With Type 2 Diabetes
Where
Capital Federal, City of Buenos Aires, Godoy Cruz, San Miguel de Tucumán
Age
10 years to 18 years
People
80 worldwide
Run by
Novo Nordisk A/S
See details and how to joinNCT07282613
Phase 3Taking people
A Master Protocol to Investigate Efficacy and Safety of Elecoglipron in Participants With Obesity or Overweight With or Without T2DM
Where
Buenos Aires, CABA, Capital Federal, Granadero Baigorria, Lanus, Rosario, San Nicolás, San Vicente
Age
18 years and over
People
4,500 worldwide
Run by
AstraZeneca
See details and how to joinNCT07667803
Phase 3Taking people
A Research Study to Look at How Two Different Doses of CagriSema and One Dose of Semaglutide Help People Living With Obesity With or Without Type 2 Diabetes Lose Weight
Where
Buenos Aires, CABA, Capital Federal, Ciudad Autónoma de Buenos Aires, Ciudad de Buenos Aires, San Miguel de Tucumán, Santa Fe, Santiago del Estero
Age
18 years and over
People
2,500 worldwide
Run by
Novo Nordisk A/S
See details and how to joinNCT07564414 · EU 2025-522488-14-00
Phase 3Taking people
A Study of Eloralintide (LY3841136) in Participants With Obesity, or Overweight Without Type 2 Diabetes
Where
Buenos Aires, Córdoba, Rosario, San Miguel de Tucumán
Age
18 years and over
People
1,980 worldwide
Run by
Eli Lilly and Company
See details and how to joinNCT07321886 · EU 2025-523657-34-00
Phase 3Taking people
AMBITION 7: A Research Study Investigating How Well Zenagamtide Lowers Blood Sugar and Body Weight Compared to Insulin Glargine in People With Type 2 Diabetes and Increased Risk of Diseases That Affect the Heart and Blood Vessels Treated With 1-3 Other Diabetes Medications
Where
Bahía Blanca, Buenos Aires, CABA, Ciudad Autonoma de Buenos Aires, Ciudad Autónoma de Buenos Aires, Córdoba, Godoy Cruz, Mar del Plata, Rosario, San Juan, San Miguel de Tucumán, San Rafael
Age
45 years and over
People
1,778 worldwide
Run by
Novo Nordisk A/S
See details and how to joinNCT07797335
Phase 3Taking people
A Phase III Study to Investigate the Efficacy and Safety of Elecoglipron Alone or in Combination With Dapagliflozin Compared With Placebo in Adults With Type 2 Diabetes Mellitus
Where
Buenos Aires, CABA, Ciudad de Buenos Aires, Mar del Plata, San Nicolás, Santa Fe, San Vicente
Age
18 years and over
People
800 worldwide
Run by
AstraZeneca
See details and how to joinNCT07662044 · EU 2025-523936-37-00
Phase 3Taking people
A Study of Dulaglutide (LY2189265) 3.0 mg and 4.5 mg in Pediatric Participants With Type 2 Diabetes Mellitus (AWARD-PEDS PLUS)
Where
Buenos Aires, Mar del Plata, Rosario, San Miguel de Tucumán, San Nicolás
Age
10 years to 17 years
People
55 worldwide
Run by
Eli Lilly and Company
See details and how to joinNCT06739122
No phaseTaking people
Study of Adult Patients Residing in Argentina Diagnosed With Type 2 Diabetes Treated With a New Formulation of Semaglutide, Both Oral and Subcutaneous, in a Real-world Setting at 3 Months, 6 Months, and 1 Year of Follow-up, Quantifying the Reduction in Glycated Hemoglobin
Where
Buenos Aires
Age
18 years and over
People
145
Run by
Hospital Italiano de Buenos Aires
See details and how to joinNCT07621419
Phase 2Taking people
A Research Study Comparing How Well Different Doses of the Medicine NNC0519-0130 Can Reduce Kidney Damage in People Living With Chronic Kidney Disease
Where
City of Buenos Aires, Corrientes, Lanús Este, Mar del Plata
Age
18 years and over
People
465 worldwide
Run by
Novo Nordisk A/S
See details and how to joinNCT06717698 · EU 2024-510846-15-00